Introduction:
Asimov, a company focused on engineering mammalian systems for the design and manufacture of therapeutics, has introduced two new products to address challenges associated with lentivirus manufacture. Lentivirus production often involves complex and inefficient processes such as transfecting GMP plasmids into cells. Asimov’s new service, called LV Edge Producer cell line development, eliminates the need for GMP plasmid transfection and generates clones with high unconcentrated lentiviral titers. Additionally, Asimov launched the LV Edge Packaging system, which allows for a single plasmid transfection and provides more control over the transfection process. Both products aim to reduce manufacturing costs and complexity associated with lentiviral production.
- Technologies for cell and gene therapy development still face challenges in lentivirus manufacture, particularly with GMP plasmids and the transfection process.
- Asimov’s LV Edge Producer cell line development service eliminates the need for GMP plasmid transfection and generates clones with high lentiviral titers.
- The LV Edge Packaging system allows for single plasmid transfection and provides more control over the transfection process.
- Both products aim to reduce manufacturing costs and complexity associated with lentiviral production.
- Asimov’s technology is primarily focused on engineered cell therapies for cancer treatment, but there is increasing demand for ex vivo cell engineering in oncology.
Conclusion:
Asimov’s introduction of the LV Edge Producer cell line development service and the LV Edge Packaging system addresses challenges in lentivirus manufacture by eliminating the need for GMP plasmid transfection and providing more control over the transfection process. These products aim to reduce manufacturing costs and complexity, making lentiviral production more economical and accessible for a range of applications in cell and gene therapy development.
